Brain Tumors Research Today is a free monthly online journal that collates and summarizes the latest research about Brain Tumors, including details on symptoms, benign and malignant tumors, gliomas, screening, treatment.

Volume 4 (2007), Issue 5 (May)

1. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.
   J Clin Oncol, 25(13): 1651-7. [Abstract] [Full-text]
2. SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas.
   Clin Cancer Res, 13(9): 2738-44. [Abstract] [Full-text]
3. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91.
   Clin Cancer Res, 13(9): 2651-7. [Abstract] [Full-text]
4. Association between functional EGF+61 polymorphism and glioma risk.
   Clin Cancer Res, 13(9): 2621-6. [Abstract] [Full-text]
5. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
   Clin Cancer Res, 13(9): 2606-13. [Abstract] [Full-text]
6. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2.
   Clin Cancer Res, 13(9): 2592-8. [Abstract] [Full-text]
7. Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients.
   Brain, 130: 1338-49. [Abstract] [Full-text]
8. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.
   J Nucl Med, 48(5): 736-43. [Abstract] [Full-text]
9. Dynamic history of low-grade gliomas before and after temozolomide treatment.
   Ann Neurol, 61(5): 484-90. [Abstract] [Full-text]
10. Intracystic bleomycin therapy for craniopharyngioma in children: the Canadian experience.
    Cancer, 109(10): 2124-31. [Abstract] [Full-text]
11. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
    J Mol Med, 85(5): 497-509. [Abstract] [Full-text]
12. Peptide-based immunotherapeutic approaches to glioma: a review.
    Expert Opin Biol Ther, 7(5): 645-9. [Abstract] [Full-text]
13. Trigemino-cardiac reflex during transsphenoidal surgery for pituitary adenomas: methodological description of a prospective skull base study protocol.
    Brain Res, 1149: 69-75. [Abstract] [Full-text]
14. IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients.
    J Neuropathol Exp Neurol, 66(5): 405-17. [Abstract] [Full-text]
15. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.
    Cancer Res, 67(9): 4467-73. [Abstract] [Full-text]
16. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.
    Cancer Res, 67(9): 4190-8. [Abstract] [Full-text]
17. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
    Cancer Res, 67(9): 4010-5. [Abstract] [Full-text]
18. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors.
    Cancer Res, 67(9): 4005-9. [Abstract] [Full-text]
19. Metastatic hemangiopericytoma to the cauda equina: a case report.
    Spine J, 7(3): 371-3. [Abstract] [Full-text]
20. Metabotropic glutamate receptors: new targets for the control of tumor growth?
    Trends Pharmacol Sci, 28(5): 206-13. [Abstract] [Full-text]
21. Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma.
    J Clin Endocrinol Metab, 92(5): 1934-7. [Abstract] [Full-text]
22. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient.
    J Clin Endocrinol Metab, 92(5): 1592-9. [Abstract] [Full-text]
23. The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations.
    J Clin Endocrinol Metab, 92(5): 1948-51. [Abstract] [Full-text]
24. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas.
    J Clin Endocrinol Metab, 92(5): 1952-5. [Abstract] [Full-text]
25. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families.
    J Clin Endocrinol Metab, 92(5): 1891-6. [Abstract] [Full-text]
26. De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival.
    Neuropathol Appl Neurobiol, 33(3): 299-307. [Abstract] [Full-text]
27. A double three-step theory of brain metastasis in mice: the role of the pia mater and matrix metalloproteinases.
    Neuropathol Appl Neurobiol, 33(3): 288-98. [Abstract] [Full-text]
28. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
    Expert Rev Anticancer Ther, 7(5): 675-87. [Abstract] [Full-text]
29. Treatment of newly diagnosed diffuse brain stem gliomas in children: in search of the holy grail.
    Expert Rev Anticancer Ther, 7(5): 663-74. [Abstract] [Full-text]
30. Molecularly targeted therapies for malignant gliomas: advances and challenges.
    Expert Rev Anticancer Ther, 7(5): 641-61. [Abstract] [Full-text]
31. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults.
    Int J Radiat Oncol Biol Phys, 68(2): 433-40. [Abstract] [Full-text]
32. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain.
    Cancer, 109(8): 1668-75. [Abstract] [Full-text]
33. Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma.
    Int J Radiat Oncol Biol Phys, 68(2): 441-8. [Abstract] [Full-text]
34. A dosimetric evaluation of conventional helmet field irradiation versus two-field intensity-modulated radiotherapy technique.
    Int J Radiat Oncol Biol Phys, 68(2): 621-31. [Abstract] [Full-text]
35. CNS germ cell tumor (CNSGCT) of childhood: presentation and delayed diagnosis.
    Neurology, 68(20): 1668-73. [Abstract] [Full-text]
36. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
    Cancer Immunol Immunother, 56(8): 1215-23. [Abstract] [Full-text]
37. Secretagogin expression in tumours of the human brain and its coverings.
    APMIS, 115(4): 319-26. [Abstract] [Full-text]
38. MicroRNA and brain tumors: a cause and a cure?
    DNA Cell Biol, 26(5): 301-10. [Abstract] [Full-text]
39. Improved preoperative evaluation of cerebral cavernomas by high-field, high-resolution susceptibility-weighted magnetic resonance imaging at 3 Tesla: comparison with standard (1.5 T) magnetic resonance imaging and correlation with histopathological findings--preliminary results.
    Invest Radiol, 42(6): 346-51. [Abstract] [Full-text]
40. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
    Cancer Res, 67(10): 4732-41. [Abstract] [Full-text]
41. Faithful companions: a proposal for neurooncology trials in pet dogs.
    Cancer Res, 67(10): 4541-4. [Abstract] [Full-text]
42. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors?
    Neurol Res, 29(3): 324-30. [Abstract] [Full-text]
43. The role of microglia/macrophage system in the tissue response to I-125 interstitial brachytherapy of cerebral gliomas.
    Neurol Res, 29(3): 233-8. [Abstract] [Full-text]
44. Brain metastases: old problem, new strategies.
    Hematol Oncol Clin North Am, 21(2): 369-88. [Abstract] [Full-text]
45. Image fusion of fluid-attenuated inversion recovery magnetic resonance imaging sequences for surgical image guidance.
    Surg Neurol, 67(6): 589-603; discussion 603. [Abstract] [Full-text]
46. Is the image guidance of ultrasonography beneficial for neurosurgical routine?
    Surg Neurol, 67(6): 579-87; discussion 587-8. [Abstract] [Full-text]
47. Cerebral microvessel perfusion and pathologic alteration of the brain during drowsiness and coma caused by brain tumor: a laboratory study on rats.
    Surg Neurol, 67(6): 564-71; discussion 571. [Abstract] [Full-text]
48. Localizing and lateralizing language in patients with brain tumors: feasibility of routine preoperative functional MR imaging in 81 consecutive patients.
    Radiology, 243(3): 828-36. [Abstract] [Full-text]
49. Low spin-lock field T1 relaxation in the rotating frame as a sensitive MR imaging marker for gene therapy treatment response in rat glioma.
    Radiology, 243(3): 796-803. [Abstract] [Full-text]
50. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
    Neurology, 68(21): 1831-6. [Abstract] [Full-text]
51. The human subventricular zone: a source of new cells and a potential source of brain tumors.
    Exp Neurol, 205(2): 313-24. [Abstract] [Full-text]
52. Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy.
    Cancer, 109(11): 2308-14. [Abstract] [Full-text]
53. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS).
    Cancer, 109(9): 1855-62. [Abstract] [Full-text]
54. Primary Ewing sarcoma of the brain: a case report and literature review.
    Diagn Mol Pathol, 16(2): 108-11. [Abstract] [Full-text]
55. Epigenetic inactivation of the hMLH1 gene in progression of gliomas.
    Diagn Mol Pathol, 16(2): 104-7. [Abstract] [Full-text]
56. Expression of the water channel protein aquaporin-9 in malignant brain tumors.
    Appl Immunohistochem Mol Morphol, 15(2): 193-8. [Abstract] [Full-text]
57. Understanding the role of the tumour vasculature in the transport of drugs to solid cancer tumours.
    Cell Prolif, 40(3): 283-301. [Abstract] [Full-text]
58. An 11-bp duplication in the promoter region of the VHL gene in a patient with cerebellar hemangioblastoma and renal oncocytoma.
    J Hum Genet, 52(6): 485-91. [Abstract] [Full-text]
59. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue.
    Pediatr Blood Cancer, 49(1): 34-40. [Abstract] [Full-text]
60. A rapid assay for drug sensitivity of glioblastoma stem cells.
    Biochem Biophys Res Commun, 358(3): 908-13. [Abstract] [Full-text]
61. Mechanisms of disease: genetic predictors of response to treatment in brain tumors.
    Nat Clin Pract Oncol, 4(6): 362-74. [Abstract] [Full-text]
62. Aberrant over-expression of a forkhead family member, FOXO1A, in a brain tumor cell line.
    BMC Cancer, 7: 67. [Abstract] [Full-text]
63. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm.
    J Clin Oncol, 25(16): 2306-12. [Abstract] [Full-text]
64. Chemotherapy delivery issues in central nervous system malignancy: a reality check.
    J Clin Oncol, 25(16): 2295-305. [Abstract] [Full-text]

© 2004-2008 Brain Tumors Research Today. All Rights Reserved.